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A B S T R A C T
Purpose: To report on a case of uveitis and scleritis resulting as an immune-mediated side effect of cancer
immunotherapy with nivolumab and cabiralizumab.
Observations: Bilateral anterior nongranulomatous anterior uveitis and bilateral diffuse anterior and posterior
scleritis occurred following the use of combination cancer immunotherapy. The uveitis and scleritis resolved
following temporary discontinuation of nivolumab and cabiralizumab as well as systemic prednisone.
Conclusions and importance: Ophthalmologists should be aware of the possibility of acute ocular inflammation
developing with cancer immunotherapy. Systemic corticosteroids play a first-line role in managing such im-
mune-mediated side effects.
1. Introduction
Cancer immunotherapy has emerged as a novel therapeutic treat-
ment option in a variety of neoplasms. With the advent of monoclonal
antibodies that target the checkpoint protein, programmed cell death
protein 1 (PD-1), in T-cells, has increased the survival rate for patients
with certain lung and renal cancers and melanomas.1 Its use continues
to expand to other neoplastic processes. Monoclonal antibodies tar-
geting macrophage colony stimulating factor 1 (CSF-1) have also been
developed. However, because PD-1 and CSF-1 are involved in med-
iating inflammatory responses, immune-mediate side effects are pos-
sible. Uveitis has been recently described to occur with the use of the
PD-1 inhibitors.2–4
Nivolumab (BMS-936558) (Opdivo, Bristol-Myers Squibb Co.) is a
monoclonal antibody that binds to PD-1 receptors on T-cells thereby
preventing the inhibition of T-cell mediated anti-tumor responses.
Cabiralizumab (FPA008) is a monoclonal antibody targeting macro-
phages and monocytes. The combination of cabiralizumab and nivo-
lumab is being used synergistically in phase 1a/1b clinical trials against
selected malignancies, including renal cell carcinoma (ClinicalTrial.gov
Identifier: NCT02526017). Potential immune-mediated adverse events
including pneumonitis, vitiligo, colitis, hepatitis, and thyroiditis have
been reported to occur in 44% of patients treated with nivolumab.1
While uveitis has been reported with the use of nivolumab,5 scleritis has
not been previously reported to occur with nivolumab or cabir-
alizumab.
2. Case report
A 66-year-old Caucasian man presented to the Proctor Foundation
for complaints of bilateral ocular pain and light sensitivity starting 5
days prior to presentation. His past ocular history was notable for early
nuclear sclerotic cataracts. His past medical history included a history
of iron deficiency anemia, hypothyroidism, and metastatic renal cell
carcinoma, clear cell type with sarcomatoid features requiring left ne-
phrectomy with metastases to the lungs. He was enrolled into a clinical
trial and commenced on the combination of cabiralizumab and nivo-
lumab two months prior to presentation. A computed tomographic scan
of the chest, abdomen, and pelvis performed on the day of his referral to
the Proctor Foundation (per clinical trial protocol) revealed an interval
improvement in his metastatic lesions. The Oncology service noted that
the patient also exhibited bilateral periorbital edema.
Spectacle-corrected visual acuity measured 20/40 OU. While there
was mild periorbital edema (Fig. 1a), ocular motility was full OU, there
was no APD, and intraocular pressure measured 12mm Hg OD and
13mm Hg OS by applanation. Slit lamp examination revealed a bi-
lateral diffuse anterior scleritis (Fig. 1a). There were fine, non-
granulomatous keratic precipitates inferiorly OU, 1 + cell and
1 + flare OU. Both irides exhibited multiple areas of posterior sy-
nechiae (Fig. 1b). There was ½+ anterior vitreous cell OU. Dilated
funduscopic examination showed no vitreous haze in either eye, flat
disc and macula OU, and flat periphery OU. B-scan ultrasonography
revealed posterior scleritis characterized by a T-sign (Fig. 2).
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After discussion with the patient's oncologists, we commenced
prednisone 60 mg PO daily and prednisolone acetate 1% QID OU.
Within one week, both anterior and posterior scleritis became inactive
clinically and on B scan ultrasonography. Anterior chamber cell im-
proved to 0.5 + OU. His prednisone was decreased by 10 mg each
week. Oncology held further administration of his cancer im-
munotherapy while the patient was taking systemic prednisone per
their protocol.
3. Discussion
While ocular side effects of PD-1 and CSF-1 inhibitors are con-
sidered rare, immune-mediated inflammatory processes affecting var-
ious organs not involved with the target neoplasm do occur. This case
demonstrates that diffuse anterior scleritis and nongranulomatous
anterior uveitis can occur in the setting of synergistic cancer
immunotherapy. Moreover, B-scan ultrasonography should be con-
sidered in such cases as it is effective in identifying posterior scleritis
even when then clinical examination of the posterior segment is rela-
tively unremarkable.
4. Conclusions
Prednisone can play an important role in managing the ocular in-
flammation that can manifest with cancer immunotherapy. While re-
currences of inflammation are known to occur2 a balance between
managing ocular inflammation while treating the underlying cancer
must be struck.
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Fig. 1. Periorbital edema was more prominent OD (a). Both eyes exhibited diffuse
anterior scleritis as represented here in OD (a). Posterior synechiae were present in both
eyes as represented here in OD (b).
Fig. 2. B scan ultrasonography demonstrated T-sign (black arrow) in both eyes (OD
shown).
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